Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts
The immune response to heterologous coronavirus disease (COVID-19) vaccination in people living with HIV (PLWH) is still unclear. Herein, our prospective cohort study aimed to compare the immune response of heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) between PLWH ha...
Saved in:
| Main Authors: | Sorawit Chittrakarn, Pisud Siripaitoon, Sarunyou Chusri, Siripen Kanchanasuwan, Boonsri Charoenmak, Thanaporn Hortiwakul, Phaiwon Kantikit, Narongdet Kositpantawong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2309734 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination
by: Amira Muftah, et al.
Published: (2024-12-01) -
Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection
by: Zdzisława Kondera-Anasz, et al.
Published: (2025-07-01) -
Relationships and Activities. The study is supported by OOO AstraZeneca Pharmaceuticals.
by: E. V. Shlyakhto, et al.
Published: (2023-07-01) -
Middle Cerebral Artery Dissection after AstraZeneca COVID-19 Vaccination
by: Hsin-Wei Wu, et al.
Published: (2025-04-01) -
Case report of secondary T-cell deficiency following the AstraZeneca COVID-19 vaccine
by: Amin Esmailian, BSC (Hons), MD, et al.
Published: (2024-11-01)